Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Xiaoou Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Histones, Brain Stem Neoplasms, Glioma, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Municipal Public Welfare Development.
Abstract (Originalsprache)
Background
Brainstem gliomas (BSGs) harboring a histone 3 lysine27-to-methionine (H3K27M) mutation represent one of the deadliest brain tumors with a dismal prognosis, as they exhibit a much worse response to therapy compared to the wildtype BSGs. Early noninvasive recognition of the H3K27M mutation is paramount for clinical decision-making in treating BSGs.
Methods
Plasma and urine samples were prospectively collected from BSG patients before biopsy or surgical resection and were chronologically divided into discovery, test, and validation cohorts. Utilizing the discovery and test cohort samples, an untargeted metabolomic strategy was exploited to identify candidate metabolite biomarkers, related to the H3K27M mutation. The candidate biomarkers were validated in the validation cohort with a targeted metabolomic method.
Results
Differential metabolomic profiles were detected between the H3K27M-mutant and wild-type BSGs in both the plasma and urine, the metabolomic changes were more dramatic in urine than in plasma. After rigorous screening for candidate biomarkers and validation with a targeted metabolomic approach, 3 metabolites, nomilin, Lys–Leu, and Hawkinsin, emerged as significantly elevated biomarkers in H3K27M-mutant BSG urine samples. The biomarker panel combining the 3 metabolites had a diagnostic area under the curve (AUC) of approximately 75%. Furthermore, the biomarker panel improved the prediction accuracy of radiomics/clinical models to an AUC value as high as 93.38%.
Conclusions
A urinary metabolite biomarker panel that exhibited high accuracy for noninvasive prediction of the H3K27M mutation status in BSG patients was identified. This panel has the potential to improve the predictive performance of current radiomics models or clinical features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Proteomics Center, Core Facility of Instrument, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
- Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Wei Sun, Liwei Zhang
Förderung
- Beijing Municipal Public Welfare Development
Zitieren
APA
Li, X., Sun, W., Guo, Z., Qi, F., Li, T., Wang, Y., Zhang, M., Wang, A., Jiang, Z., Xie, L., Mai, Y., Wang, Y., Wu, Z., Ji, N., Zhang, Y., & Zhang, L. (2025). Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf038
Vancouver
Li X, Sun W, Guo Z, Qi F, Li T, Wang Y, et al. Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf038
BibTeX
@article{Li2025,
author = {Li, Xiaoou and Sun, Wei and Guo, Zhengguang and Qi, Feng and Li, Tian and Wang, Yujin and Zhang, Mingxin and Wang, Aiwei and Jiang, Zhuang and Xie, Luyang and Mai, Yiying and Wang, Yi and Wu, Zhen and Ji, Nan and Zhang, Yang and Zhang, Liwei},
title = {Identification of urinary metabolic biomarkers for histone 3 lysine27-to-methionine mutation diagnosis in brainstem gliomas},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf038}
}
EUVIMED